Literature DB >> 8794392

Lymphoproliferative responses after infection with human parvovirus B19.

A von Poblotzki1, C Gerdes, U Reischl, H Wolf, S Modrow.   

Abstract

Immunity after infection with the parvovirus B19 is assumed to be conferred by a humoral immune response with development of neutralizing antibody. In contrast, little is known about the nature of T-cell-mediated responses to parvovirus B19 infection in humans. We used recombinant proteins VP1, VP2, and NS1, as well as a recombinant VP1-specific amino-terminal sequence, to test the proliferative responses of peripheral blood mononuclear cells after infection of otherwise healthy individuals with parvovirus B19. These proteins were used as antigens for the stimulation of freshly isolated cells. The results show that a B19 virus-specific cellular immunity develops that is directed against the capsid proteins VP1 and VP2. We also demonstrate that viral determinants are presented to CD4+ T cells by HLA class II molecules.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794392      PMCID: PMC190798     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy.

Authors:  G Kurtzman; N Frickhofen; J Kimball; D W Jenkins; A W Nienhuis; N S Young
Journal:  N Engl J Med       Date:  1989-08-24       Impact factor: 91.245

Review 2.  Persistent parvovirus B19 infections in humans.

Authors:  N Frickhofen; N S Young
Journal:  Microb Pathog       Date:  1989-11       Impact factor: 3.738

3.  Parvovirus infections and hypoplastic crisis in sickle-cell anaemia.

Authors:  J R Pattison; S E Jones; J Hodgson; L R Davis; J M White; C E Stroud; L Murtaza
Journal:  Lancet       Date:  1981-03-21       Impact factor: 79.321

4.  Human parvovirus B19 infection in pregnancy.

Authors:  T F Schwarz; M Roggendorf; B Hottenträger; F Deinhardt; G Enders; K P Gloning; T Schramm; M Hansmann
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

5.  Human parvovirus infection in early rheumatoid and inflammatory arthritis.

Authors:  B J Cohen; M M Buckley; J P Clewley; V E Jones; A H Puttick; R K Jacoby
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

Review 6.  Human parvoviruses.

Authors:  L J Anderson
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

7.  Rheumatologic manifestations of human parvovirus B19 infection in adults. Initial two-year clinical experience.

Authors:  S J Naides; L L Scharosch; F Foto; E J Howard
Journal:  Arthritis Rheum       Date:  1990-09

8.  Immune response to B19 parvovirus and an antibody defect in persistent viral infection.

Authors:  G J Kurtzman; B J Cohen; A M Field; R Oseas; R M Blaese; N S Young
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

9.  Human parvovirus-associated arthritis: a clinical and laboratory description.

Authors:  D M Reid; T M Reid; T Brown; J A Rennie; C J Eastmond
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

10.  Human parvovirus arthropathy.

Authors:  D G White; A D Woolf; P P Mortimer; B J Cohen; D R Blake; P A Bacon
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

View more
  16 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Impaired gamma interferon responses against parvovirus B19 by recently infected children.

Authors:  A Corcoran; S Doyle; D Waldron; A Nicholson; B P Mahon
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

Review 3.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

4.  Placental cellular immune response in women infected with human parvovirus B19 during pregnancy.

Authors:  J A Jordan; D Huff; J A DeLoia
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

5.  T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.

Authors:  R Franssila; J Auramo; S Modrow; M Möbs; C Oker-Blom; P Käpylä; M Söderlund-Venermo; K Hedman
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

6.  New LightCycler PCR for rapid and sensitive quantification of parvovirus B19 DNA guides therapeutic decision-making in relapsing infections.

Authors:  T C Harder; M Hufnagel; K Zahn; K Beutel; H J Schmitt; U Ullmann; P Rautenberg
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

7.  Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19.

Authors:  T Tolfvenstam; A Oxenius; D A Price; B L Shacklett; H M Spiegel; K Hedman; O Norbeck; M Levi; K Olsen; M Kantzanou; D F Nixon; K Broliden; P Klenerman
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 8.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

9.  Immune responses to the major capsid protein during parvovirus infection of rats.

Authors:  Lisa J Ball-Goodrich; Frank X Paturzo; Elizabeth A Johnson; Krista Steger; Robert O Jacoby
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 10.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.